tradmap

ZBIO Earnings Zenas Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$24 -$12 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $25M $50M 2023 2024 2025
Revenue
Net income (annual)
-$378M -$189M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$42 -$21 $0 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $25M $50M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$240M -$102M $36M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–12 of 12
Q2 20262026-06-30-3.242026-08-1310-Q
Q1 20262026-03-31-1.462026-05-1310-Q
FY 20252025-12-31-8.442026-03-1610-K
Q3 20252025-09-30-3.272025-11-1210-Q
Q2 20262025-06-30-2.052026-08-1310-Q
Q1 20262025-03-31-0.802026-05-1310-Q
FY 20252024-12-31-11.892026-03-1610-K
Q3 20252024-09-30-28.832025-11-1210-Q
Q2 20252024-06-30-42.152025-08-1210-Q
Q1 20252024-03-31-17.892025-05-1510-Q
FY 20242023-12-31-24.252025-03-1110-K
Q3 20242023-09-30-8.212024-11-1210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.